Skip to Content

Stem Cell Transplant Reviewed for Peripheral T-Cell Lymphoma

THURSDAY, June 10, 2021 -- For patients with refractory or relapsed peripheral T-cell lymphoma (R/R-PTCL), three- and five-year overall survival (OS) and progression-free survival (PFS) are similar with allogeneic or autologous hematopoietic stem cell transplant (HSCT), but transplant-related mortality (TRM) is higher with allogeneic HSCT, according to a review published online May 27 in JAMA Network Open.

Jun Du, M.D., from the Chinese Academy of Medical Sciences and Peking Union Medical College in Tianjin, China, and colleagues conducted a systematic review of the literature and meta-analysis to compare the effectiveness and safety of allogeneic HSCT versus autologous HSCT among patients with R/R-PTCL. Thirty trials were included in the meta-analysis, with 880 and 885 patients undergoing allogeneic and autologous HSCT, respectively.

The researchers found that the three-year OS and PFS were 50 and 42 percent, respectively; five-year OS and PFS were 54 and 48 percent, respectively; and three-year TRM was 32 percent in the allogeneic HSCT group. The three-year OS and PFS were 55 and 41 percent, respectively; five-year OS and PFS were 53 and 40 percent, respectively; and three-year TRM was 7 percent in the autologous HSCT group.

"The data from this meta-analysis provide evidence that for select patients with PTCL, both autologous HSCT and allogeneic HSCT may be a potentially effective approach to treatment," write the authors of an accompanying editorial. "This meta-analysis falls short of providing a rigorous, risk-segmented analysis of which modality is more likely to be most effective for a particular patient."

Abstract/Full Text


© 2021 HealthDay. All rights reserved.

Read this next

Breyanzi Approved for Certain Types of Large B-Cell Lymphoma

MONDAY, Feb. 8, 2021 -- Cell-based gene therapy Breyanzi (lisocabtagene maraleucel) has been approved to treat adults with certain types of large B-cell lymphoma who have not...

ASH: CAR T-Cell Therapy Promising for Relapsed/Refractory iNHL

WEDNESDAY, Dec. 9, 2020 -- Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, is promising for the treatment of...

Rates of VTE, Major Bleeding High in Primary CNS Lymphoma

FRIDAY, Nov. 20, 2020 -- For patients with primary central nervous system lymphoma (PCNSL), the incidence of venous thromboembolism (VTE) and major bleeding is high, according to...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.